Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy
Authors' conclusion
Among patients with IIM, the presence of ILD was linked to higher mortality. Certain autoantibodies, notably anti-ARS and anti-Ro-52 antibodies, were associated with an increased risk of ILD. The greatest risk of ILD was observed in cases of dual positivity for anti-ARS and anti-Ro-52 antibodies.
Study context
- Population
- Patients who underwent myositis autoantibody testing between July 2018 and January 2021 at one hospital, diagnosed with IIM or IIM-mimics
- Participants
- 604 patients
- Exposure
- IIM vs IIM-mimics; within IIM, interstitial lung disease (ILD) vs no ILD and myositis antibody categories
- IIMn = 190
- IIM-mimicsn = 414reference
- Outcome
- Occurrence of ILD in IIM, by myositis antibody category
Methodological detailssingle-centre, logistic regression or Firth's logistic regression
- Single-centre
- Logistic regression or Firth's logistic regression
Main finding
As reported in the abstract
Risk of ILD by antibody category in IIM
- Any myositis-specific antibody (MSA): increased risk of ILD
- six-fold
- Dual positivity MSA + anti-Ro-52: risk of ILD
- twenty-fold
- Anti-ARS: increased risk of ILD
- 14-fold
- Dual positivity anti-ARS + anti-Ro-52: risk of ILD
- 38-fold
- Anti-Ro-52 alone: increased risk of ILD
- eight-fold
Observational data: associations, not effects.
Further findings
IIM vs IIM-mimics
- IIM: higher incidence of ILD, concurrent autoimmune disease, and greater likelihood of various myositis autoantibodies vs IIM-mimics
IIM with vs without ILD
- ILD: later age of IIM onset, increased mortality, more frequent anti-ARS antibodies vs without ILD
Original publication
Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy. Arthritis Res Ther. Published 22 August 2024. doi:10. 1186/ s13075-024-03382-x
Composed by AI from the published abstract and checked against it. How Briefs are made →